Loading...

Acacia Pharma Group plc

ACPH.BR•EURONEXT
HealthcareBiotechnology
$0.89
$0.00(0.00%)

Acacia Pharma Group plc (ACPH.BR) Stock Overview

Explore Acacia Pharma Group plc’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for ACPH.BRStats details for ACPH.BR are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for ACPH.BRAnalyst Recommendations details for ACPH.BR are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Acacia Pharma Group plc discovers, develops, and commercializes pharmaceutical products for the patients undergoing surgery, invasive procedures, or chemotherapy treatments in the United States and internationally. The company's lead product is BARHEMSYS, an intravenous amisulpride for the treatment and prophylaxis of post-operative nausea and vomiting. Its products also include BYFAVO, an intravenous remimazolam and reversible IV sedative designed for use during invasive medical procedures, such as colonoscopy and bronchoscopy; and APD403, a selective dopamine antagonist amisulpride that has completed Phase II clinical trials for the treatment of chemotherapy-induced nausea and vomiting. Acacia Pharma Group plc was founded in 2007 and is based in Cambridge, the United Kingdom.

CEO

Mr. Michael Bolinder

Employees

76

Headquarters

The Officers Mess Business Centre, Royston Road, Cambridge, CAMBRIDGESHIRE

Founded

2018

Frequently Asked Questions

Meyka LogoMeyka

Meyka is the best Alternative Data platform powered by AI providing research insights for investors

Connect With Us

Legal

Resources

Market

Legal Disclaimer

The information provided by Meyka AI PTY LTD is for informational and research purposes only and does not constitute financial, investment, or trading advice. Meyka is a research platform, not a financial advisory service. Investing in financial markets involves risks, and past performance does not guarantee future results. Users should conduct their own due diligence, consult with professional financial advisors, and assess their risk tolerance before making investment decisions. Meyka and its operators are not liable for any financial losses incurred from the use of information on this platform. The data provided is derived from publicly available sources and is believed to be reliable but may not always be accurate or up to date. Users should independently verify information and not rely solely on Meyka for financial decisions. By using Meyka, you acknowledge that it does not provide financial advice or recommendations and agree to seek guidance from a qualified financial professional before making any investment decisions.

© 2025 Meyka AI PTY LTD. All rights reserved.